Janux Therapeutics Inc (JANX)
45.35
-0.14
(-0.31%)
USD |
NASDAQ |
May 22, 16:00
45.36
+0.02
(+0.03%)
After-Hours: 20:00
Janux Therapeutics SG&A Expense (Quarterly): 7.343M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.343M |
| December 31, 2023 | 6.357M |
| September 30, 2023 | 6.438M |
| June 30, 2023 | 6.881M |
| March 31, 2023 | 6.464M |
| December 31, 2022 | 5.677M |
| September 30, 2022 | 6.098M |
| June 30, 2022 | 5.54M |
| March 31, 2022 | 4.947M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.937M |
| September 30, 2021 | 3.656M |
| June 30, 2021 | 1.997M |
| March 31, 2021 | 0.739M |
| December 31, 2020 | 0.67M |
| September 30, 2020 | 0.422M |
| June 30, 2020 | 0.433M |
| March 31, 2020 | 0.277M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.277M
Minimum
Mar 2020
7.343M
Maximum
Mar 2024
3.993M
Average
4.947M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
| Viking Therapeutics Inc | 9.97M |
| Equillium Inc | 3.737M |
| Minerva Neurosciences Inc | 2.515M |
| Arvinas Inc | 24.30M |
| Calidi Biotherapeutics Inc | 4.009M |